Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7399941 | 0.98 | L3MBTL1 (0.60) | L3MBTL1RAB9APOLBTSHRLMNA | |
| SCHEMBL9053634 | 0.98 | L3MBTL1 (0.60) | L3MBTL1RAB9APOLBTSHRLMNA | |
| SCHEMBL1127670 | 0.95 | L3MBTL1 (0.63) | L3MBTL1RAB9APOLBTSHRLMNA | |
| SCHEMBL65336 | 0.88 | TSHR (0.63) | L3MBTL1RAB9APOLBTSHRLMNA | |
| SCHEMBL24757440 | 0.85 | CYP1A2 (0.48) | L3MBTL1RAB9APOLBTSHRLMNA | |
| SCHEMBL24757426 | 0.85 | CYP1A2 (0.48) | L3MBTL1RAB9APOLBTSHRLMNA | |
| SCHEMBL23152727 | 0.84 | PAOX (0.60) | L3MBTL1RAB9APOLBTSHRLMNA | |
| SCHEMBL27065452 | 0.83 | ALDH1A1 (0.48) | L3MBTL1RAB9ATSHRALDH1A1TDP1 | |
| SCHEMBL7418522 | 0.83 | CYP1A2 (0.50) | L3MBTL1RAB9APOLBALDH1A1CYP1A2 | |
| SCHEMBL1127803 | 0.83 | PAOX (0.59) | L3MBTL1RAB9APOLBTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3415151-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | The University of British Columbia (CA) | 2018-12-19 | — | — | EP | disclosed |
| EP-2282724-B1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-09-05 | — | — | EP | disclosed |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-9968554-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-15 | — | — | US | disclosed |
| US-9968554-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-15 | — | — | US | disclosed |
| US-9062002-B2 | Substituted pyridine derivatives as FabI inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-06-23 | — | — | US | disclosed |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-12-04 | — | — | US | disclosed |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-12-04 | — | — | US | disclosed |
| US-20140336153-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2014-11-13 | — | — | US | disclosed |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-07-07 | — | — | US | disclosed |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-07-07 | — | — | US | disclosed |
| EP-2282724-A2 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | The University Of British Columbia (CA) | 2011-02-16 | — | — | EP | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| WO-2009141738-A2 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141738-A2 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-11-26 | — | — | WO | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| CN-1671379-A | Hydrazinopyrazole derivatives and their use as therapeutic agents | QUADRA LOGIC TECH INC (CA) | 2005-09-21 | — | — | CN | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336153-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | F12, FAR1, NQO2 | L3MBTL1 1410/4885RAB9A 2539/4885POLB 2133/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | L3MBTL1 1450/4885RAB9A 3555/4885POLB 1409/4885 |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | ABCB11, SLC47A1, ABCB1 | L3MBTL1 226/4885RAB9A 149/4885POLB 2779/4885 |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | L3MBTL1 226/4885RAB9A 149/4885POLB 2779/4885 |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | L3MBTL1 226/4885RAB9A 149/4885POLB 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.